Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Authors||Janice Chen, Christopher L. Brooks, Peter McDonald, Jonathan D. Schwartz, Keiichi Sakakibara, Naoya Saito...Takuji Sato, Takumi Kawabe, Eric Keith Rowinsky|
|Title||Preclinical activity of SL-801, a reversible inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) in solid and hematologic cancers|
|Journal||Journal of Clinical Oncology|
|Abstract Text||Journal of Clinical Oncology 33, no. 15_suppl|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SL-801||SL-801 is a small molecule inhibitor of XPO1, which prevents substrates from binding to XPO1, thereby disrupting the nuclear export of proteins, and thus, may lead to inhibition of tumor growth (Journal of Clinical Oncology 33, no. 15_suppl).|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||SL-801||Preclinical - Cell line xenograft||Actionable||In a preclinical study, SL-801 resulted in tumor growth inhibition in xenograft models with various advanced solid tumors (Journal of Clinical Oncology 33, no. 15_suppl).||detail...|